早期利妥昔单抗单药治疗对比观察等待用于晚期、无症状、低肿瘤负荷滤泡性淋巴瘤:一项随机3期试验的长期结果
这项在5个国家118个中心开展的开放标签随机3期试验,纳入455例晚期无症状低肿瘤负荷滤泡性淋巴瘤患者,随机分入观察等待组、利妥昔单抗诱导组和利妥昔单抗维持组。中位随访14.7年时,15年未开始新治疗的比例在维持组为65%、诱导组为48%、观察等待组为34%;两利妥昔单抗组至新治疗时间均长于观察等待组。
要点
- 15年时未开始新治疗比例:利妥昔单抗维持组65%、诱导组48%、观察等待组34%。
- 至新治疗时间:维持组 vs 观察等待组 HR 0.36(95%CI 0.26-0.50),p<0.0001。
- 至新治疗时间:诱导组 vs 观察等待组 HR 0.55(95%CI 0.38-0.80),p=0.0019。
核心结论
- 中位随访14.7年的成熟数据证实,早期利妥昔单抗单药治疗可大幅延迟晚期无症状低肿瘤负荷滤泡性淋巴瘤患者开始新治疗的需求,为其在此场景中的应用提供证据基础,并确认其对希望推迟或避免化疗的患者的价值。
研究设计与样本
- 开放标签、随机、3期试验,在5个国家118个中心开展,纳入455例无症状、II-IV期、1-3a级低肿瘤负荷滤泡性淋巴瘤且ECOG体能状态0-1的成人患者。
- 患者按1:1:1随机分入观察等待组(183例)、利妥昔单抗诱导组(82例;375 mg/m2静脉给药,每周一次共4次)和利妥昔单抗维持组(190例;诱导后以相同剂量每8周一次共12次维持)。
- 利妥昔单抗诱导组于2007年9月30日提前关闭,研究修正为两组试验;主要终点为至新治疗时间(TTNT),在意向治疗人群中评估。
- 研究注册号ClinicalTrials.gov NCT00112931,入组与随访已完成;2004年10月15日至2009年5月1日随机分配455例。
主要发现
- 中位随访14.7年(IQR 13.3-15.6)。
- 15年时未开始新治疗的患者比例:利妥昔单抗维持组65%(95%CI 56-72),利妥昔单抗诱导组48%(95%CI 36-60),观察等待组34%(95%CI 27-42)。
- 中位TTNT:利妥昔单抗维持组未达到(95%CI 15.6-不可估计),利妥昔单抗诱导组14.8年(95%CI 7.5-未达到),观察等待组5.6年(95%CI 3.8-8.4)。
- TTNT在利妥昔单抗诱导组和维持组均长于观察等待组:诱导组 vs 观察等待组 HR 0.55(95%CI 0.38-0.80),p=0.0019;维持组 vs 观察等待组 HR 0.36(95%CI 0.26-0.50),p<0.0001。
临床怎么用
- 这些成熟数据为早期利妥昔单抗单药治疗用于晚期无症状低肿瘤负荷滤泡性淋巴瘤提供了证据基础,并确认其对希望推迟或避免化疗的患者的价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Initial results of this study, reported after a median follow-up close to 4 years, demonstrated improved time to initiation of new treatment (TTNT) for patients with advanced stage, asymptomatic, low tumour burden follicular lymphoma who received early rituximab monotherapy when compared with watchful waiting. Given the long natural history of follicular lymphoma, the trial was extended to further assess TTNT with longer follow-up. Mature data are presented here. METHODS: In this open-label, randomised, phase 3 trial, conducted at 118 centres in five countries, adult patients with asymptomatic, stage II-IV, grade 1-3a low tumour burden follicular lymphoma and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned (1:1:1) between watchful waiting, rituximab induction (375 mg/m2, intravenous) weekly for four doses (rituximab induction group) and rituximab induction followed by rituximab maintenance at the same dose every 8 weeks for 12 doses (rituximab maintenance group). The rituximab induction group closed early on Sept 30, 2007, and the study was amended to a two-arm trial. The primary endpoint was TTNT, assessed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT00112931, and recruitment and follow-up are complete. FINDINGS: Between Oct 15, 2004, and May 1, 2009, 455 patients were randomly assigned, including 183 to watchful waiting, 82 to rituximab induction, and 190 to rituximab maintenance. Median follow-up was 14·7 years (IQR 13·3-15·6). At 15 years, 65% (95% CI 56-72) of patients in the rituximab maintenance group, 48% (36-60) in the rituximab induction group, and 34% (27-42) in the watchful waiting group had not started new treatment. Median TTNT was not yet reached (95% CI 15·6-not estimable) in the rituximab maintenance group, 14·8 years (7·5-not reached) in the rituximab induction group, and 5·6 years (3·8-8·4) in the watchful waiting group. TTNT was longer in both the rituximab induction and rituximab maintenance groups compared with the watchful waiting group (rituximab induction vs watchful waiting: hazard ratio [HR] 0·55 [95% CI 0·38-0·80], p=0·0019; rituximab maintenance vs watchful waiting: HR 0·36 [0·26-0·50], p<0·0001). INTERPRETATION: These mature data with 15 years of follow-up confirm that early rituximab monotherapy substantially delays the need for new treatment for patients with advanced stage, asymptomatic low tumour burden follicular lymphoma, providing an evidence base for its use in this setting and confirming its value for patients who seek to defer or avoid treatment with chemotherapy. FUNDING: Cancer Research UK, Lymphoma Research Trust, Lymphoma Association, and Roche.
引用
- Northend M, Wilson W, Ediriwickrema K, et al. Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial. Lancet Haematol. 2025. PMID: 40306831. doi:10.1016/S2352-3026(25)00034-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。